Erectile Dysfunction Drugs Market - Global Industry Analysis

Erectile Dysfunction Drugs Market By Therapeutics (Existing drugs, Tadalafil, Sildenafil Citrate Vardenafil, Udenafil, Stendra/Spedra, Lodenafil Carbonate, Mirodenafil Pipeline drugs, Apomorphine, Alprostadil, Topiglan, Gene Therapy, and Melanocortin Activators), and By Region – Global and Regional Industry Overview, Market Intelligence, Comprehensive Analysis, Historical Data, and Forecasts 2022 – 2028

Published Date: 30-May-2022 Category: Pharmaceutical Report Format : PDF Pages: 190 Report Code: ZMR-3395 Status : Published

The global erectile dysfunction drugs market reached nearly USD 3.64 billion in 2021 and is projected to expand with a compound annual growth rate (CAGR) of approximately 6.9 percent over the forecast period to grow by about USD 5.94 billion by 2028.

Description

Industry Prospective:

The global erectile dysfunction drugs market reached nearly USD 3.64 billion in 2021 and is projected to expand with a compound annual growth rate (CAGR) of approximately 6.9 percent over the forecast period to grow by about USD 5.94 billion by 2028. This global report is packed with key drivers and opportunities that can spur market growth during the forecast period. Along with this detailed study on major market, restrains & challenges and their cumulative impact is also discussed in the report. The report also covers all the regional market studies with revenue and market share for major countries.

Erectile Dysfunction Drugs Market: Overview

Erectile dysfunction is the incapability to attain and maintain a hard erection for sexual activity. Having problems with erection isn't usually a reason for fear. However, if erectile dysfunction is a long-term condition, it can create stress, lower self-esteem, and lead to marital issues. Problems obtaining or maintaining an erection can be a symptom of a more serious underlying health issue, as well as a possible risk for cardiovascular disease. To treat such conditions several drugs are available on the market that can help to maintain the erection during sexual intercourse. With a change in lifestyle and increased stress conditions need for these drugs is on the rise.

COVID-19 Impact:

Demand for erectile dysfunction drugs increased during the COVID-19 pandemic period. The research conducted and published during the pandemic period stated in men with ED, COVID-19 is more than five times more prevalent. Also, men with a history of COVID-19 had a 5-fold increased chance of having ED. As a result, the COVID-19 has a considerable influence on the market for erectile dysfunction drugs. The demand for these drugs is expected to remain high post-COVID-19 pandemic.

Erectile Dysfunction Drugs Market

Erectile Dysfunction Drugs Market: Growth Drivers

Growth in embracing poor lifestyle choices may boost the market growth over the forecast period.

With the surge in the adoption of a bad lifestyle, diabetes, obesity, and cardiovascular disease are on the rise, which in turn leads to problems like ED as people become older. The present lifestyle of youth in many emerging countries is very stressful resulting in increased alcoholism, smoking, and fast food or ready-to-eat food consumption. Due to these factors, overall health and fitness are getting compromised which in turn increases the chances of ED. Furthermore, as the senior population grows, so does the number of ED patients, which is a significant driver of the global erectile dysfunction drugs market throughout the projection period.

Erectile Dysfunction Drugs Market: Restraints

Low awareness and side effects associated with erectile dysfunction drugs may hinder the market growth.

Erectile dysfunction drugs are majorly sold in developed and emerging economies; however, the percentage of their sale is less in low- and middle-income countries. This is mainly due to less knowledge about these types of medication, low buying power, and less willingness to adopt such kinds of medications in lifestyle. Furthermore, side effects associated with these drugs such as headache, upset stomach, flushing, nasal congestion, vision problems, dizziness, diarrhea, and rash also contribute to the slow growth of the market.

Erectile Dysfunction Drugs Market: Opportunities

Increased pharmaceutical manufacturing in emerging countries is likely to offer better growth opportunities for market expansion.

In the last couple of years, major and emerging brands in pharmaceutical industries have increased their investments in emerging countries like India, China, Africa, and major Middle East countries. This has significantly lowered the cost of medicine along with the supply and the distribution of drugs within the countries which is expected to offer significance. Furthermore, increased investments in advertisements are also likely to contribute significantly to the expansion of the global erectile dysfunction drugs market.

Report Scope:

Report Attribute Details
Base Year 2020
Historic Years 2016 - 2020
Forecast Years 2021 - 2028
Segments Covered By Product Type, By Application, and By End Use
Forecast Units Value (USD Billion), and Volume (Units)
Quantitative Units Revenue in USD million/billion and CAGR from 2021 to 2028
Regions Covered North America, Europe, Asia Pacific, Latin America, and Middle East & Africa, and Rest of World
Countries Covered U.S., Canada, Mexico, U.K., Germany, France, Italy, Spain, China, India, Japan, South Korea, Brazil, Argentina, GCC Countries, and South Africa, among others
Number of Companies Covered 10 companies with scope for including additional 15 companies upon request
Report Coverage Market growth drivers, restraints, opportunities, Porter’s five forces analysis, PEST analysis, value chain analysis, regulatory landscape, market attractiveness analysis by segments and region, company market share analysis, and COVID-19 impact analysis.
Customization Scope Avail customized purchase options to meet your exact research needs.

Erectile Dysfunction Drugs Market: Challenges.

An increase in the availability of counterfeit erectile dysfunction medicines poses a major challenge to the market expansion.

The expanding manufacture of generic erectile dysfunction pharmaceuticals, as well as the growing availability of bogus erectile dysfunction drugs, are two important challenges for the market. Consumers typically choose lower-cost generic erectile dysfunction pills over more expensive blockbuster kinds due to the profitable marketing of counterfeit erectile dysfunction drugs at considerably cheaper prices than either patented or generic pharmaceuticals. Aside from that, when patents on blockbuster pharmaceuticals expire, new generic equivalents are entering the market, generally at inexpensive rates.

Erectile Dysfunction Drugs Market: Segmentation

The global erectile dysfunction market is categorized based on therapeutics and region. By therapeutics, the global erectile dysfunction market is bifurcated into Existing drugs, Tadalafil, Sildenafil Citrate Vardenafil, Udenafil, Stendra/Spedra, Lodenafil Carbonate, Mirodenafil Pipeline drugs, Apomorphine, Alprostadil, Topiglan, Gene Therapy, and Melanocortin Activators.

Recent Developments

May 2020, Metuchen Pharmaceuticals, L.L.C., a privately owned biopharmaceutical aimed at defining, developing, gaining, and commercializing revolutionary therapeutics for male sexual health conditions, and Neurotrope, Inc. ("Neurotrope") officially revealed that the two firms have decided to enter into a concise merger agreement within which Metuchen and Neurotrope, Inc. will unite in an all-stock purchase arising in a newly formed partnership firm ("Petros"). Petros is anticipated to become a Nasdaq-listed corporation specializing in men's health.

Erectile Dysfunction Drugs Market: Regional Landscape

North America is projected to lead the global market over the forecast period.

North America is likely to dominate the global erectile dysfunction drugs market. This is mainly due to the expanding senior population and superior healthcare infrastructure, as per a Rural Health Information Center report released in April 2019 stated that there are more than 46 million older persons in the United States, with that figure predicted to climb to about 90 million by 2050. When the last of the baby boom cohorts reach 65, the number of older individuals is predicted to climb by roughly 18 million between 2020 and 2030. Because ED is particularly frequent in men over the age of 40, the rise in the elderly male population is predicted to increase the number of individuals suffering from it. The domination of these countries is due to the availability of numerous ED medicines by OTC and internet outlets. The National Institute of Diabetes and Digestive and Kidney Diseases stated roughly 30 million men in the United States suffer from ED. Furthermore, the United States has the greatest rate of self-reported ED. As a result, rising ED prevalence in the US is likely to fuel market growth throughout the projection period.

Erectile Dysfunction Drugs Market: Competitive Landscape

Major players operating in the global erectile dysfunction drugs market include Eli Lilly & Co., Pfizer, Dong-A Pharmaceutical Co. Ltd, Bayer AG, Meda Pharmaceuticals, Vivus, Inc., and Apricus Biosciences.

Global erectile dysfunction drugs market is segmented as follows:

By Therapeutics

  • Existing drugs
  • Tadalafil
  • Sildenafil Citrate Vardenafil
  • Udenafil
  • Stendra/Spedra
  • Lodenafil Carbonate
  • Mirodenafil Pipeline drugs
  • Apomorphine
  • Alprostadil
  • Topiglan
  • Gene Therapy
  • Melanocortin Activators

By Region

  • North America
    • The U.S.
    • Canada
  • Europe
    • France 
    • The UK
    • Spain
    • Germany
    • Italy
    • Rest of Europe
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Southeast Asia
    • Rest of Asia Pacific
  • Latin America
    • Brazil
    • Mexico
    • Rest of Latin America
  • Middle East & Africa
    • GCC
    • South Africa
    • Rest of Middle East & Africa

Table Of Content

  • Chapter 1. Preface
    • 1.1 Report Description and Scope
    • 1.2 Research scope
    • 1.3 Research methodology
      • 1.3.1 Market Research Type
      • 1.3.2 Market research methodology
  • Chapter 2. Executive Summary
    • 2.1 Global Erectile Dysfunction Drugs Market, (2022 - 2028) (USD Billion)
    • 2.2 Global Erectile Dysfunction Drugs Market : snapshot
  • Chapter 3. Global Erectile Dysfunction Drugs Market - Industry Analysis
    • 3.1 Erectile Dysfunction Drugs Market: Market Dynamics
    • 3.2 Market Drivers
      • 3.2.1 Growth in embracing poor lifestyle choices may boost the market growth over the forecast period.
    • 3.3 Market Restraints
      • 3.3.1. Low awareness and side effects associated with erectile dysfunction drugs may hinder the market growth.
    • 3.4 Market Opportunities
      • 3.4.1. Increased pharmaceutical manufacturing in emerging countries is likely to offer better growth opportunities for market expansion.
    • 3.5 Market Challenges
      • 3.5.1. An increase in the availability of counterfeit erectile dysfunction medicines poses a major challenge to the market expansion.
    • 3.6 Porter’s Five Forces Analysis
    • 3.7 Market Attractiveness Analysis
      • 3.7.1 Market attractiveness analysis By Therapeutics
  • Chapter 4. Global Erectile Dysfunction Drugs Market- Competitive Landscape
    • 4.1 Company market share analysis
      • 4.1.1 Global Erectile Dysfunction Drugs Market: company market share, 2021
    • 4.2 Strategic development
      • 4.2.1 Acquisitions & mergers
      • 4.2.2 New Product launches
      • 4.2.3 Agreements, partnerships, cullaborations, and joint ventures
      • 4.2.4 Research and development and Regional expansion
    • 4.3 Price trend analysis
  • Chapter 5. Global Erectile Dysfunction Drugs Market - Therapeutics Analysis
    • 5.1 Global Erectile Dysfunction Drugs Market overview: By Therapeutics
      • 5.1.1 Global Erectile Dysfunction Drugs Market share, By Therapeutics, 2021 and 2028
    • 5.2 Existing drugs
      • 5.2.1 Global Erectile Dysfunction Drugs Market by Existing drugs, 2022 - 2028 (USD Billion)
    • 5.3 Tadalafil
      • 5.3.1 Global Erectile Dysfunction Drugs Market by Tadalafil, 2022 - 2028 (USD Billion)
    • 5.4 Sildenafil Citrate Vardenafil
      • 5.4.1 Global Erectile Dysfunction Drugs Market by Sildenafil Citrate Vardenafil, 2022 - 2028 (USD Billion)
    • 5.5 Udenafil
      • 5.5.1 Global Erectile Dysfunction Drugs Market by Udenafil, 2022 - 2028 (USD Billion)
    • 5.6 Stendra/Spedra
      • 5.6.1 Global Erectile Dysfunction Drugs Market by Stendra/Spedra, 2022 - 2028 (USD Billion)
    • 5.7 Lodenafil Carbonate
      • 5.7.1 Global Erectile Dysfunction Drugs Market by Lodenafil Carbonate, 2022 - 2028 (USD Billion)
    • 5.8 Mirodenafil Pipeline drugs
      • 5.8.1 Global Erectile Dysfunction Drugs Market by Mirodenafil Pipeline drugs, 2022 - 2028 (USD Billion)
    • 5.9 Apomorphine
      • 5.9.1 Global Erectile Dysfunction Drugs Market by Apomorphine, 2022 - 2028 (USD Billion)
    • 5.10 Alprostadil
      • 5.10.1 Global Erectile Dysfunction Drugs Market by Alprostadil, 2022 - 2028 (USD Billion)
    • 5.11 Topiglan
      • 5.11.1 Global Erectile Dysfunction Drugs Market by Topiglan, 2022 - 2028 (USD Billion)
    • 5.12 Gene Therapy
      • 5.12.1 Global Erectile Dysfunction Drugs Market by Gene Therapy, 2022 - 2028 (USD Billion)
    • 5.13 Melanocortin Activators
      • 5.13.1 Global Erectile Dysfunction Drugs Market by Melanocortin Activators, 2022 - 2028 (USD Billion)
  • Chapter 6. Erectile Dysfunction Drugs Market - Regional Analysis
    • 6.1 Global Erectile Dysfunction Drugs Market Regional Overview
    • 6.2 Global Erectile Dysfunction Drugs Market Share, by Region, 2021 & 2028 (USD Billion)
    • 6.3. North America
      • 6.3.1 North America Erectile Dysfunction Drugs Market, 2022 - 2028 (USD Billion)
        • 6.3.1.1 North America Erectile Dysfunction Drugs Market, by Country, 2022 - 2028 (USD Billion)
    • 6.4 North America Erectile Dysfunction Drugs Market, by Therapeutics, 2022 - 2028
      • 6.4.1 North America Erectile Dysfunction Drugs Market, by Therapeutics, 2022 - 2028 (USD Billion)
    • 6.4. Europe
      • 6.4.2 Europe Erectile Dysfunction Drugs Market, 2022 - 2028 (USD Billion)
        • 6.4.2.1 Europe Erectile Dysfunction Drugs Market, by Country, 2022 - 2028 (USD Billion)
    • 6.4 Europe Erectile Dysfunction Drugs Market, by Therapeutics, 2022 - 2028
      • 6.4.1 Europe Erectile Dysfunction Drugs Market, by Therapeutics, 2022 - 2028 (USD Billion)
    • 6.5. Asia Pacific
      • 6.5.3 Asia Pacific Erectile Dysfunction Drugs Market, 2022 - 2028 (USD Billion)
        • 6.5.3.1 Asia Pacific Erectile Dysfunction Drugs Market, by Country, 2022 - 2028 (USD Billion)
    • 6.4 Asia Pacific Erectile Dysfunction Drugs Market, by Therapeutics, 2022 - 2028
      • 6.4.1 Asia Pacific Erectile Dysfunction Drugs Market, by Therapeutics, 2022 - 2028 (USD Billion)
    • 6.6. Latin America
      • 6.6.4 Latin America Erectile Dysfunction Drugs Market, 2022 - 2028 (USD Billion)
        • 6.6.4.1 Latin America Erectile Dysfunction Drugs Market, by Country, 2022 - 2028 (USD Billion)
    • 6.4 Latin America Erectile Dysfunction Drugs Market, by Therapeutics, 2022 - 2028
      • 6.4.1 Latin America Erectile Dysfunction Drugs Market, by Therapeutics, 2022 - 2028 (USD Billion)
    • 6.7. The Middle-East and Africa
      • 6.7.5 The Middle-East and Africa Erectile Dysfunction Drugs Market, 2022 - 2028 (USD Billion)
        • 6.7.5.1 The Middle-East and Africa Erectile Dysfunction Drugs Market, by Country, 2022 - 2028 (USD Billion)
    • 6.4 The Middle-East and Africa Erectile Dysfunction Drugs Market, by Therapeutics, 2022 - 2028
      • 6.4.1 The Middle-East and Africa Erectile Dysfunction Drugs Market, by Therapeutics, 2022 - 2028 (USD Billion)
  • Chapter 7. Company Profiles
    • 7.1 Eli Lilly & Co.
      • 7.1.1 Overview
      • 7.1.2 Financials
      • 7.1.3 Product Portfolio
      • 7.1.4 Business Strategy
      • 7.1.5 Recent Developments
    • 7.2 Pfizer
      • 7.2.1 Overview
      • 7.2.2 Financials
      • 7.2.3 Product Portfolio
      • 7.2.4 Business Strategy
      • 7.2.5 Recent Developments
    • 7.3 Dong-A Pharmaceutical Co. Ltd
      • 7.3.1 Overview
      • 7.3.2 Financials
      • 7.3.3 Product Portfolio
      • 7.3.4 Business Strategy
      • 7.3.5 Recent Developments
    • 7.4 Bayer AG
      • 7.4.1 Overview
      • 7.4.2 Financials
      • 7.4.3 Product Portfolio
      • 7.4.4 Business Strategy
      • 7.4.5 Recent Developments
    • 7.5 Meda Pharmaceuticals
      • 7.5.1 Overview
      • 7.5.2 Financials
      • 7.5.3 Product Portfolio
      • 7.5.4 Business Strategy
      • 7.5.5 Recent Developments
    • 7.6 Vivus Inc.
      • 7.6.1 Overview
      • 7.6.2 Financials
      • 7.6.3 Product Portfolio
      • 7.6.4 Business Strategy
      • 7.6.5 Recent Developments
    • 7.7 Apricus Biosciences.
      • 7.7.1 Overview
      • 7.7.2 Financials
      • 7.7.3 Product Portfolio
      • 7.7.4 Business Strategy
      • 7.7.5 Recent Developments

Table Of Figures

  • 1. Market research Type
  • 2. Market research methodology
  • 3. Global Erectile Dysfunction Drugs Market, 2022 - 2028 (USD Billion)
  • 4. Porter’s Five Forces Analysis
  • 5. Global Erectile Dysfunction Drugs Market attractiveness, By Therapeutics
  • 6. Global Erectile Dysfunction Drugs Market share by Therapeutics, 2022 and 2028 (USD Billion)
  • 7. Global Erectile Dysfunction Drugs Market by Existing drugs, 2022 - 2028 (USD Billion)
  • 8. Global Erectile Dysfunction Drugs Market by Tadalafil, 2022 - 2028 (USD Billion)
  • 9. Global Erectile Dysfunction Drugs Market by Sildenafil Citrate Vardenafil, 2022 - 2028 (USD Billion)
  • 10. Global Erectile Dysfunction Drugs Market by Udenafil, 2022 - 2028 (USD Billion)
  • 11. Global Erectile Dysfunction Drugs Market by Stendra/Spedra, 2022 - 2028 (USD Billion)
  • 12. Global Erectile Dysfunction Drugs Market by Lodenafil Carbonate, 2022 - 2028 (USD Billion)
  • 13. Global Erectile Dysfunction Drugs Market by Mirodenafil Pipeline drugs, 2022 - 2028 (USD Billion)
  • 14. Global Erectile Dysfunction Drugs Market by Apomorphine, 2022 - 2028 (USD Billion)
  • 15. Global Erectile Dysfunction Drugs Market by Alprostadil, 2022 - 2028 (USD Billion)
  • 16. Global Erectile Dysfunction Drugs Market by Topiglan, 2022 - 2028 (USD Billion)
  • 17. Global Erectile Dysfunction Drugs Market by Gene Therapy, 2022 - 2028 (USD Billion)
  • 18. Global Erectile Dysfunction Drugs Market by Melanocortin Activators, 2022 - 2028 (USD Billion)
  • 19. Global Erectile Dysfunction Drugs Market share, by Region, 2022 and 2028
  • 20. North America Erectile Dysfunction Drugs Market, 2022 - 2028 (USD Billion)
  • 21. Europe Erectile Dysfunction Drugs Market, 2022 - 2028 (USD Billion)
  • 22. Asia Pacific Erectile Dysfunction Drugs Market, 2022 - 2028 (USD Billion)
  • 23. Latin America Erectile Dysfunction Drugs Market, 2022 - 2028 (USD Billion)
  • 24. The Middle-East and Africa Erectile Dysfunction Drugs Market, 2022 - 2028 (USD Billion)

Table Of Tables

  • 1. Global Erectile Dysfunction Drugs Market: Snapshot
  • 2. Drivers of the Erectile Dysfunction Drugs Market: impact analysis
  • 3. North America Erectile Dysfunction Drugs Market revenue, By Therapeutics, 2022 - 2028 (USD Billion)
  • 4. U.S. Erectile Dysfunction Drugs Market revenue, By Therapeutics, 2022 - 2028 (USD Billion)
  • 5. Canada Erectile Dysfunction Drugs Market revenue, By Therapeutics, 2022 - 2028 (USD Billion)
  • 6. Europe Erectile Dysfunction Drugs Market revenue, By Therapeutics, 2022 - 2028 (USD Billion)
  • 7. Germany Erectile Dysfunction Drugs Market revenue, By Therapeutics, 2022 - 2028 (USD Billion)
  • 8. France Erectile Dysfunction Drugs Market revenue, By Therapeutics, 2022 - 2028 (USD Billion)
  • 9. U.K. Erectile Dysfunction Drugs Market revenue, By Therapeutics, 2022 - 2028 (USD Billion)
  • 10. Italy Erectile Dysfunction Drugs Market revenue, By Therapeutics, 2022 - 2028 (USD Billion)
  • 11. Spain Erectile Dysfunction Drugs Market revenue, By Therapeutics, 2022 - 2028 (USD Billion)
  • 12. Rest of Europe Erectile Dysfunction Drugs Market revenue, By Therapeutics, 2022 - 2028 (USD Billion)
  • 13. Asia Pacific Erectile Dysfunction Drugs Market revenue, By Therapeutics, 2022 - 2028 (USD Billion)
  • 14. China Erectile Dysfunction Drugs Market revenue, By Therapeutics, 2022 - 2028 (USD Billion)
  • 15. Japan Erectile Dysfunction Drugs Market revenue, By Therapeutics, 2022 - 2028 (USD Billion)
  • 16. India Erectile Dysfunction Drugs Market revenue, By Therapeutics, 2022 - 2028 (USD Billion)
  • 17. South Korea Erectile Dysfunction Drugs Market revenue, By Therapeutics, 2022 - 2028 (USD Billion)
  • 18. South-East Asia Erectile Dysfunction Drugs Market revenue, By Therapeutics, 2022 - 2028 (USD Billion)
  • 19. Rest of Asia Pacific Erectile Dysfunction Drugs Market revenue, By Therapeutics, 2022 - 2028 (USD Billion)
  • 20. Latin America Erectile Dysfunction Drugs Market revenue, By Therapeutics, 2022 - 2028 (USD Billion)
  • 21. Brazil Erectile Dysfunction Drugs Market revenue, By Therapeutics, 2022 - 2028 (USD Billion)
  • 22. Mexico Erectile Dysfunction Drugs Market revenue, By Therapeutics, 2022 - 2028 (USD Billion)
  • 23. Rest of Latin America Erectile Dysfunction Drugs Market revenue, By Therapeutics, 2022 - 2028 (USD Billion)
  • 24. The Middle-East and Africa Erectile Dysfunction Drugs Market revenue, By Therapeutics, 2022 - 2028 (USD Billion)
  • 25. GCC Countries Erectile Dysfunction Drugs Market revenue, By Therapeutics, 2022 - 2028 (USD Billion)
  • 26. South Africa Erectile Dysfunction Drugs Market revenue, By Therapeutics, 2022 - 2028 (USD Billion)
  • 27. Rest of Middle-East Africa Erectile Dysfunction Drugs Market revenue, By Therapeutics, 2022 - 2028 (USD Billion)

Methodology

Free Analysis

Erectile dysfunction (ED) is mainly the lack of ability to maintain or achieve the erection sufficiently. Aging is one of the leading factor responsible for impeding the normal function of erection. Besides, hypertension, diabetes mellitus, cardiovascular diseases, excess medications, and spinal cord injuries are some of the other factors that are found to be responsible for the cause of erectile dysfunction. However, today’s medicinal products for treating erectile dysfunction are far-fetched in many ways. They are effective, safe, and have helped millions of men to regain their sexual self-confidence. In spite of the fact that ED has received attention in the recent years, only 10 to 15% men with ED have received the right treatment. There is still a large population of patients who still need medication for ED, but due to various reasons have not yet got help.

Due to the considerable rise in the revenue of erectile dysfunction drugs, over last decade, more than 31 chemical moieties have advanced in the therapeutic pipeline from which 90% of molecules or drugs are developed by companies and only 10% of these are developed by research institutes and medical universities. However, the growth in clinical trials for these molecules and drugs is still insufficient to tackle the unmet needs of treatment in low-income countries for the global erectile dysfunction drugs market. One of the challenges faced by the mid-level pharma companies is the lack of presence across the globe due to the presence of top companies leading the market for erectile dysfunction. However many companies are now implicated in the expansion of their erectile dysfunction product portfolio through joint ventures and acquisition policies. For instance, in May 2017 Lupin Ltd. launched Cialis ED drug through a licensing agreement with Eli Lilly. In this alliance, Eli Lilly will be responsible for manufacturing and importing the product in India. Some of the private equity firms are also interested in buying American Medical Systems which is one of the leading manufacturers of products used to treat pelvic disorders for both male and female, laser technology devices, and erectile dysfunction prostheses.

Global Erectile Dysfunction Drugs Market

The erectile dysfunction drugs market is segmented based on the type of drug, mode of administration, and by distribution channel. Based on the type of drug, the market is segmented into Sildenafil Citrate (Viagra), Mirodenafil (Mvix), Vardenafil (Levitra/ Staxyn), Tadalafil (Cialis), Udenafil (Zydena), Stendra/ Spedra (Avanafil), Lodenafil Carbonate (Helleva), and others. Based on the mode of administration, the market for erectile dysfunction drugs is bifurcated into oral medications, topical medications, injections, and others. Based on the distribution channel, the market is segmented into online sales, hospital pharmacies, and retail pharmacies.

North America holds the largest share in the erectile dysfunction drugs market. This growth is mainly attributed to the huge number of R&D activities in the field of drug discovery carried out by this region. The region also has a large presence of a number of multinational pharma companies which carry out a large number of clinical trials and also have well developed and advanced healthcare infrastructure. Due to high healthcare investment and rising government funding Europe also holds a maximum share of the market followed by North America. Numerous big names are actively involved in the expansion of existing erectile dysfunction drugs to meet the rising demands for treatment of this disease. Besides, approval of new drugs for treating ED disorders by the European Union is also fuelling the market for erectile dysfunction drugs in Europe. Asia Pacific region is also witnessing significant growth rate owing to the unmet health care needs and raised government funding towards research activities. Moreover, changes in lifestyle, smoking, excessive alcohol consumption, and obesity are other factors responsible for market growth. Increasing awareness about erectile dysfunction through various marketing campaigns and CME programs continuing medical education is encouraging people to visit medical professionals and seek treatment for erectile dysfunction and associated problems. These developments are expected to positively support growth prospects in the Asia Pacific region for erectile dysfunction drugs market.

Some of the leading players in erectile dysfunction drugs market include Apricus Biosciences, Bayer AG, Cristália, Eli Lilly and Company, Inc., Pfizer, Inc., Dong-A-Pharmaceutical Co., Ltd., S.K. Chemicals Co., Ltd., Vivus, Inc., Teva Pharmaceutical Industries Ltd., and Meda Pharmaceuticals, Inc. Pfizer, Inc. Competitors are focusing on the development of novel product manufacturing which might show the faster onset of the action which has minimum side effects as compared to the existing therapies. However, in near future, patent expiration of leading brands can increase the competition for generic drugs at cheap prices and give other manufacturers opportunities to come up with their products in the market.

Choose License Type

Request the coronavirus impact analysis across industries and markets

Request impact analysis
on this market

RelatedNews

FrequentlyAsked Questions

With the surge in the adoption of a bad lifestyle, diabetes, obesity, and cardiovascular disease are on the rise, which in turn leads to problems like ED as people become older. The present lifestyle of youth in many emerging countries is very stressful that resulting in increased alcoholism, smoking, and fast food or ready-to-eat food consumption. Due to these factors, overall health and fitness are getting compromised which in turn increases the chances of ED. Furthermore, as the senior population grows, so does the number of ED patients, which is a significant driver of the global erectile dysfunction drugs market throughout the projection period.

According to the Zion Market Research report, the global erectile dysfunction drugs market was worth about 3.64 (USD billion) in 2021 and is predicted to grow to around 5.94 (USD billion) by 2028, with a compound annual growth rate (CAGR) of around 6.9 percent.

North America is likely to dominate the global erectile dysfunction drugs market. This is mainly due to the expanding senior population and superior healthcare infrastructure, as per a Rural Health Information Center report released in April 2019 stated that there are more than 46 million older persons in the United States, with that figure predicted to climb to about 90 million by 2050. When the last of the baby boom cohorts reach 65, the number of older individuals is predicted to climb by roughly 18 million between 2020 and 2030. Because ED is particularly frequent in men over the age of 40, the rise in the elderly male population is predicted to increase the number of individuals suffering from it.

Major players operating in the global erectile dysfunction drugs market include Eli Lilly & Co., Pfizer, Dong-A Pharmaceutical Co. Ltd, Bayer AG, Meda Pharmaceuticals, Vivus, Inc., and Apricus Biosciences.

HappyClients

Office Address

Contact Us

Zion Market Research
Tel: +1 (844) 845-5245
USA/Canada Toll Free No.+1 (855) 465-4651

Asia Pacific Office

3rd Floor, Mrunal Paradise, Opp Maharaja Hotel, Pimple Gurav, Pune 411061, Maharashtra, India
Phone No 020-46277770

Contact #

US OFFICE NO +1 (844) 845-5245
US/CAN TOLL FREE +1 (855) 465-4651
Email: sales@zionmarketresearch.com

We Are On Social

Industry Press Release

We Accept

We have secured system to process your transaction.

  • paypal
  • amazon
  • visa
  • master card

How it Works?

Our Company

Business Hours

Our support available to help you 24 hours a day, five days a week.

Monday - Friday: 9AM - 6PM

Saturday - Sunday: Closed